Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Alfred Lammens Clear advanced filters

  • The targeted development of proteome-wide selective covalent probes remains a challenge. Here, the authors show the exploration of the natural product Sulphostin as a starting point for dipeptidyl peptidase 8 and 9 inhibitor development.

    • Leonard Sewald
    • Werner W. A. Tabak
    • Markus Kaiser
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-15

  • X-ray crystallography, cryo-electron microscopy, structural modelling, biochemistry, cell biology, and evolutionary analysis enable characterization of ORF2p, the reverse transcriptase of the ancient ‘parasitic’ LINE-1 retrotransposon that has written around one-third of the human genome.

    • Eric T. Baldwin
    • Trevor van Eeuwen
    • Martin S. Taylor
    ResearchOpen Access
    Nature
    Volume: 626, P: 194-206

  • The RNase activity of Inositol-Requiring Enzyme 1 (IRE1) can be allosterically regulated by ATP-competitive inhibitors of the IRE1 kinase domain. Here, the authors identify ATP-competitive IRE1 RNase activators with improved selectivity and cellular activity, and elucidate their mechanism of action.

    • Elena Ferri
    • Adrien Le Thomas
    • Weiru Wang
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-15

  • BAFF is an important cytokine for B cell survival, and is a therapeutic target for autoimmune disorders. Here the authors show that a 'flap' region of BAFF converts BAFFR binding events into survival signals and, with structural data, that this ‘flap’ differentially modulates binding of drugs such as belimumab or atacicept.

    • Michele Vigolo
    • Melissa G. Chambers
    • Pascal Schneider
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-15